Analysis of comorbid factors that increase the COPD assessment test scores

Respiratory Research

Tomoko Betsuyaku¹  Koichiro Asano⁶  Paul W Jones⁷  Koichi Sayama¹  Takeshi Terashima⁸  Fumio Sakamaki⁵  Morio Nakamura³  Hidefumi Koh²  Naoto Minematsu¹  Saeko Takahashi¹  Toru Shirahata¹  Keishi Tsuduki¹  Shuichi Yoshida¹  Mizuha Haraguchi¹  Mamoru Sasaki¹  Shotaro Chubachi¹  Hidetoshi Nakamura⁴  Masaki Miyazaki¹ 

[1] Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan;Saiseikai Utsunomiya Hospital, Tochigi, Japan;Eiju General Hospital, Tokyo, Japan;Department of Respiratory Medicine, Saitama Medical University, Saitama, Japan;Tokyo Saiseikai Central Hospital, Tokyo, Japan;Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan;Division of Clinical Science, St. George’s University of London, London, UK;Department of Respiratory Medicine, Tokyo Dental College, Chiba, Japan

关键词: Osteoporosis;    Comorbidity;    Gastro-esophageal reflux;    Depression;    Health status;    Chronic obstructive pulmonary disease;   

Others  :  790649
DOI  :  10.1186/1465-9921-15-13

 received in 2013-10-01, accepted in 2014-02-03,  发布年份 2014

【 摘 要 】

Background

The chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) is a concise health status measure for COPD. COPD patients have a variety of comorbidities, but little is known about their impact on quality of life. This study was designed to investigate comorbid factors that may contribute to high CAT scores.

Methods

An observational study at Keio University and affiliated hospitals enrolled 336 COPD patients and 67 non-COPD subjects. Health status was assessed by the CAT, the St. Georges Respiratory Questionnaire (SGRQ), and all components of the Medical Outcomes Study Short-Form 36-Item (SF-36) version 2, which is a generic measure of health. Comorbidities were identified based on patients’ reports, physicians’ records, and questionnaires, including the Frequency Scale for the Symptoms of Gastro-esophageal reflux disease (GERD) and the Hospital Anxiety and Depression Scale. Dual X-ray absorptiometry measurements of bone mineral density were performed.

Results

The CAT showed moderate-good correlations with the SGRQ and all components of the SF-36. The presence of GERD, depression, arrhythmia, and anxiety was significantly associated with a high CAT score in the COPD patients.

Conclusions

Symptomatic COPD patients have a high prevalence of comorbidities. A high CAT score should alert the clinician to a higher likelihood of certain comorbidities such as GERD and depression, because these diseases may co-exist unrecognized.

Trial registration

Clinical trial registered with UMIN (UMIN000003470).

【 授权许可】

   
2014 Miyazaki et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, Zielinski J: Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
• [2]Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, Van Empel VP, Bruijnzeel PL, Rutten EP, Op’t Roodt J, Wouters EF, Franssen FM: Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:728-735.
• [3]Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, Celli B, BODE Collaborative Group: Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:155-161.
• [4]Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
• [5]Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George’s respiratory questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
• [6]Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW: A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987, 42:773-778.
• [7]Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N: Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34:648-654.
• [8]Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA: Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med 2012, 185:1218-1224.
• [9]Dodd JW, Hogg L, Nolan J, Jefford H, Grant A, Lord VM, Falzon C, Garrod R, Lee C, Polkey MI, Jones PW, Man WD, Hopkinson NS: The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 2011, 66:425-429.
• [10]Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R, Leidy NK: Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest 2012, 142:134-140.
• [11]Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler Cataluña JJ, van der Molen T, Adamek L, Banik N: Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J 2011, 38:29-35.
• [12]Jones PW, Nadeau G, Small M, Adamek L: Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Respir Med 2014, 108:129-135.
• [13]The American Thoracic Society board of directors: Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995, 152:1107-1136.
• [14]Committee of Pulmonary Physiology, the Japanese Respiratory Society: The Japanese Respiratory Society Guidelines for pulmonary function tests: spirometry, flow‒volume curve, diffusion capacity of the lung (in Japanese). Tokyo; 2004.
• [15]Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:785-790.
• [16]Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:1185-1189.
• [17]Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K: Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998, 51:1037-1044.
• [18]Danjo A, Yamaguchi K, Fujimoto K, Saitoh T, Inamori M, Ando T, Shimatani T, Adachi K, Kinjo F, Kuribayashi S, Mitsufuji S, Fujiwara Y, Koyama S, Akiyama J, Takagi A, Manabe N, Miwa H, Shimoyama Y, Kusano M: Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres. J Gastroenterol Hepatol 2009, 24:633-638.
• [19]Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Sugiyama T, Toki M, Ohwada T, Mori M: Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 2004, 39:888-891.
• [20]Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
• [21]Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, Wang C, Bourbeau J: Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 2008, 178:913-920.
• [22]Biskobing DM: COPD and osteoporosis. Chest 2002, 121:609-620.
• [23]Report of a WHO Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994, 843:1-129.
• [24]Burgel PR, Escamilla R, Perez T, Carré P, Caillaud D, Chanez P, Pinet C, Jebrak G, Brinchault G, Court-Fortune I, Paillasseur JL, Roche N: INITIATIVES BPCO scientific committee: impact of comorbidities on COPD-specific health-related quality of life. Respir Med 2013, 107:233-241.
• [25]Kwon N, Amin M, Hui DS, Jung KS, Lim SY, Ta HD, Thai TT, Jones PW: Validity of the COPD assessment test translated into local languages for Asian patients. Chest 2013, 143:703-710.
• [26]Terada K, Muro S, Sato S, Ohara T, Haruna A, Marumo S, Kinose D, Ogawa E, Hoshino Y, Niimi A, Terada T, Mishima M: Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 2008, 63:951-955.
• [27]Mokhlesi B, Morris AL, Huang CF, Curcio AJ, Barrett TA, Kamp DW: Increased prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest 2001, 119:1043-1048.
• [28]Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B: Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009, 136:1456-1465.
• [29]Ogura-Tomomatsu H, Asano K, Tomomatsu K, Miyata J, Ohmori N, Kodama M, Ueda S, Takihara T, Tanaka K, Kamiishi N, Suzuki Y, Fukunaga K, Oguma T, Sayama K, Betsuyaku T: Predictors of osteoporosis and vertebral fractures in patients presenting with moderate-to-severe chronic obstructive lung disease. COPD 2012, 9:332-337.
• [30]Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J: TORCH Investigators: Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010, 65:719-725.
• [31]Rutten FH, Moons KG, Cramer MJ, Grobbee DE, Zuithoff NP, Lammers JW, Hoes AW: Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005, 331:1379-1382.